For instance, a clinical trial demonstrated that fecal microbiota transplantation combined with anti-PD-1 therapy improved immunotherapy efficacy in certain anti-PD-1-resistant melanoma patients, possibly through increased gut microbiota, CD8+T cell activation, and decreased IL-8 inflammation (72). This evidence concerns the gene CXCL8 and melanoma.